|
|
Vol. 16.32 – 19 September, 2024
|
|
|
|
|
|
|
|
The authors identified the antioxidant enzymes NQO1 and SOD1 as therapeutic vulnerabilities of ALDH+ epithelial-like cancer stem-like cells (CSCs) and CD24-/loCD44+/hi mesenchymal-like CSCs in TNBC.
[Cancer Research]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists identified the suppression of FANCI as a therapeutic strategy to enhance the efficacy of PARP inhibitors in breast cancer.
[Cancer Research]
|
|
|
|
|
|
Researchers identified the spliceosome U2 small nuclear ribonucleoprotein particle complex as a modulator of chemotherapy efficacy in TNBC.
[Cell Reports]
|
|
|
|
|
|
Scientists demonstrated that the cell surface glycoprotein Mcam maintained the tumorigenic luminal progenitor-like epithelial cell state, leading to basal-like mammary cancers.
[NPJ Breast Cancer]
|
|
|
|
|
|
The authors observed reduction in glucose metabolism due to downregulation of AKT/mTOR signalome in activated CD8 + T cells after cancer derived exosome exposure.
[Cell Biology International]
|
|
|
|
|
|
Investigators showed that AMP dose-dependently inhibited p-nitrophenylphosphate (p-NPP) hydrolysis. The p-NPP and AMP hydrolysis showed similar biochemical behaviors, such as increased hydrolysis under acidic conditions and comparable inhibition by NiCl2, ammonium molybdate, and sodium orthovanadate.
[Cell Biology International]
|
|
|
|
|
|
Scientists compared the canine mammary tumor histone H3 lysine 4 trimethylation landscape with that in human breast cancer.
[Heliyon]
|
|
|
|
|
|
|
|
The authors comprehensively examine recent advances in breast cancer research, with a focus on classification, molecular pathways, and the role of heme oxygenases, heme metabolism implications, and therapeutic innovations.
[Molecular and Cellular Biochemistry]
|
|
|
|
|
|
|
|
Novartis announced that the US FDA has approved Kisqali® in combination with an aromatase inhibitor for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer at high risk of recurrence.
[Novartis]
|
|
|
|
|
|
|
|
October 4 – 7, 2024
St. Julians, Malta
|
|
|
|
|
|
|
|
|
|
|
University of Nevada, Las Vegas – Las Vegas, Nevada, United States
|
|
|
|
|
|
|
University of Southampton – Southampton, England, United Kingdom
|
|
|
|
|
|
|
Westlake University – Zhejiang, China
|
|
|
|
|
|
|
University of Colorado Anschutz Medical Campus – Anschutz, Colorado, United States
|
|
|
|
|
|
|
University Health Network – Toronto, Ontario, Canada
|
|
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
